“Urgent Action: PaxMedica Inc. (NASDAQ: PXMD) Addresses Medical Crisis in Malawi”
In recent developments, PaxMedica (NASDAQ: PXMD), a renowned biopharmaceutical company specializing in treatments for neurological disorders, has taken swift action to address a pressing medical situation unfolding in Malawi, East Africa. The Ministry of Health (“MOH”) of Malawi has issued a plea for access to IV suramin, a vital medication in combating the life-threatening sleeping sickness crisis affecting the region.
PaxMedica swiftly responded to this call for help by committing to provide emergency access to its recently completed registration batches of PAX-101, an IV form of suramin. This decision underscores PaxMedica’s dedication to mitigating the devastating impact of sleeping sickness and ensuring access to life-saving medications in regions facing critical shortages.
Howard Weisman, Chairman and CEO of PaxMedica, emphasized the urgent need for IV suramin in Malawi, stating, “The emergency request from the Ministry of Health of Malawi underscores the critical need for IV suramin to combat the continued devastating impact of sleeping sickness in the region.” PaxMedica’s proactive stance in responding to this crisis highlights the company’s commitment to addressing urgent healthcare needs and advancing treatments for neurological disorders on a global scale.
This recent development follows PaxMedica’s completion of three pivotal registration/validation batches of PAX-101, marking a significant milestone in the company’s ongoing development program. PaxMedica’s collaborative efforts with physicians and government bodies in Malawi and neighboring countries further demonstrate its commitment to advancing treatments for Trypanosoma brucei rhodesiense Human African trypanosomiasis (TBr HAT).
In light of these developments, PaxMedica is actively engaging with regulatory authorities in both the U.S. and Malawi to expedite its response to the urgent medical crisis. The company aims to navigate the regulatory landscape efficiently while ensuring a steady supply of suramin to address critical healthcare needs in endemic regions.
As the global community grapples with the challenges posed by infectious diseases, PaxMedica’s swift and decisive response to the urgent crisis in Malawi highlights the critical role of biopharmaceutical companies in addressing public health emergencies and advancing global healthcare initiatives.
For more information, visit the company’s website at www.PaxMedica.com.
NOTE TO INVESTORS: The latest news and updates relating to PXMD are available in the company’s newsroom at https://nnw.fm/PXMD
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
In recent developments, PaxMedica (NASDAQ: PXMD), a renowned biopharmaceutical company specializing in treatments for neurological disorders, has taken swift action to address a pressing medical situation unfolding in Malawi, East Africa. The Ministry of Health (“MOH”) of Malawi has issued a plea for access to IV suramin, a vital medication in combating the life-threatening sleeping sickness crisis affecting the region.
PaxMedica swiftly responded to this call for help by committing to provide emergency access to its recently completed registration batches of PAX-101, an IV form of suramin. This decision underscores PaxMedica’s dedication to mitigating the devastating impact of sleeping sickness and ensuring access to life-saving medications in regions facing critical shortages.
Howard Weisman, Chairman and CEO of PaxMedica, emphasized the urgent need for IV suramin in Malawi, stating, “The emergency request from the Ministry of Health of Malawi underscores the critical need for IV suramin to combat the continued devastating impact of sleeping sickness in the region.” PaxMedica’s proactive stance in responding to this crisis highlights the company’s commitment to addressing urgent healthcare needs and advancing treatments for neurological disorders on a global scale.
This recent development follows PaxMedica’s completion of three pivotal registration/validation batches of PAX-101, marking a significant milestone in the company’s ongoing development program. PaxMedica’s collaborative efforts with physicians and government bodies in Malawi and neighboring countries further demonstrate its commitment to advancing treatments for Trypanosoma brucei rhodesiense Human African trypanosomiasis (TBr HAT).
In light of these developments, PaxMedica is actively engaging with regulatory authorities in both the U.S. and Malawi to expedite its response to the urgent medical crisis. The company aims to navigate the regulatory landscape efficiently while ensuring a steady supply of suramin to address critical healthcare needs in endemic regions.
As the global community grapples with the challenges posed by infectious diseases, PaxMedica’s swift and decisive response to the urgent crisis in Malawi highlights the critical role of biopharmaceutical companies in addressing public health emergencies and advancing global healthcare initiatives.
For more information, visit the company’s website at www.PaxMedica.com.
NOTE TO INVESTORS: The latest news and updates relating to PXMD are available in the company’s newsroom at https://nnw.fm/PXMD
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
